FDA recommends taking patients off Felbatol.
D000741:Anemia, Aplastic / Q000139:chemically induced*; D000927:Anticonvulsants / Q000009:adverse effects*; D000078328:Felbamate; D006801:Humans; D048448:Phenylcarbamates; D011358:Product Surveillance, Postmarketing; D011409:Propylene Glycols / Q000009:adverse effects*; D014481:United States; D014486:United States Food and Drug Administration
D000927:Anticonvulsants; D048448:Phenylcarbamates; D011409:Propylene Glycols; D000078328:Felbamate